Tourmaline Bio (TRML) News Today → Wall Street legend who predicted 2021 tech crash issues new warning (From Chaikin Analytics) (Ad) Free TRML Stock Alerts $15.25 +0.83 (+5.76%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 9:06 AM | marketbeat.comTourmaline Bio, Inc. to Post FY2025 Earnings of ($3.35) Per Share, HC Wainwright Forecasts (NASDAQ:TRML)Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Equities researchers at HC Wainwright issued their FY2025 earnings per share estimates for Tourmaline Bio in a report released on Tuesday, May 14th. HC Wainwright analyst Y. Chen anticipates that the company will earn ($3.35) per share for the yeMay 14 at 5:45 PM | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Tourmaline Bio (TRML)May 14 at 10:45 AM | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Tourmaline Bio (NASDAQ:TRML)HC Wainwright reaffirmed a "buy" rating and set a $48.00 target price on shares of Tourmaline Bio in a report on Tuesday.May 13 at 2:33 PM | investorplace.comTRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024May 13 at 7:00 AM | globenewswire.comTourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 13 at 1:18 AM | americanbankingnews.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of "Buy" from AnalystsMay 11, 2024 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Short Interest Up 73.7% in AprilTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) was the target of a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 3,110,000 shares, a growth of 73.7% from the April 15th total of 1,790,000 shares. Currently, 20.1% of the shares of the company are sold short. Based on an average daily trading volume, of 421,300 shares, the short-interest ratio is currently 7.4 days.May 9, 2024 | marketbeat.comVivo Capital LLC Buys New Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Vivo Capital LLC purchased a new position in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 591,882 shares of the company's stock, valued at approximately $15,495,000.April 24, 2024 | marketbeat.comBML Capital Management LLC Makes New Investment in Tourmaline Bio, Inc. (NASDAQ:TRML)BML Capital Management LLC bought a new stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 245,500 shares of the company's stock, valued at apApril 12, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Trading Up 3.9%Tourmaline Bio (NASDAQ:TRML) Stock Price Up 3.9%April 11, 2024 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Short Interest Up 123.1% in MarchTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 1,480,000 shares, a growth of 123.1% from the March 15th total of 663,500 shares. Currently, 9.6% of the shares of the company are short sold. Based on an average daily volume of 359,800 shares, the days-to-cover ratio is presently 4.1 days.April 9, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Trading Down 2.3%Tourmaline Bio (NASDAQ:TRML) Trading Down 2.3%April 2, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Stock Price Down 7%Tourmaline Bio (NASDAQ:TRML) Shares Down 7%March 25, 2024 | marketbeat.comTruist Financial Reaffirms "Buy" Rating for Tourmaline Bio (NASDAQ:TRML)Truist Financial restated a "buy" rating and issued a $74.00 target price on shares of Tourmaline Bio in a research note on Monday.March 22, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Sees Strong Trading VolumeTourmaline Bio (NASDAQ:TRML) Sees Unusually-High Trading VolumeMarch 22, 2024 | seekingalpha.comTourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly BearishMarch 22, 2024 | marketbeat.comHC Wainwright Equities Analysts Increase Earnings Estimates for Tourmaline Bio, Inc. (NASDAQ:TRML)Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Analysts at HC Wainwright lifted their Q1 2024 earnings per share (EPS) estimates for Tourmaline Bio in a note issued to investors on Wednesday, March 20th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.70) per share foMarch 21, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Shares Gap Down to $44.67Tourmaline Bio (NASDAQ:TRML) Shares Gap Down to $44.67March 21, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Price Target Raised to $72.00Jefferies Financial Group raised their price objective on shares of Tourmaline Bio from $41.00 to $72.00 and gave the stock a "buy" rating in a report on Wednesday.March 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tourmaline Bio Amidst Promising Clinical Trials and Drug Candidate ProspectsMarch 20, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Shares Gap Up to $40.33Tourmaline Bio (NASDAQ:TRML) Shares Gap Up to $40.33March 20, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $48.00 price target on shares of Tourmaline Bio in a research note on Wednesday.March 19, 2024 | investorplace.comTRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023March 19, 2024 | globenewswire.comTourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsMarch 16, 2024 | ca.finance.yahoo.comTRML Apr 2024 55.000 callMarch 15, 2024 | finance.yahoo.comTRML Apr 2024 20.000 putMarch 15, 2024 | finance.yahoo.comTRML Apr 2024 35.000 putMarch 15, 2024 | finance.yahoo.comTRML Apr 2024 50.000 callMarch 14, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Trading Down 8.7%Tourmaline Bio (NASDAQ:TRML) Trading Down 8.7%March 13, 2024 | markets.businessinsider.comTruist Financial Gives a Buy Rating to Tourmaline Bio (TRML)March 12, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Reaches New 12-Month High at $43.75Tourmaline Bio (NASDAQ:TRML) Hits New 52-Week High at $43.75March 12, 2024 | finance.yahoo.comTRML Mar 2024 60.000 putMarch 12, 2024 | ca.finance.yahoo.comTRML Apr 2024 25.000 putMarch 4, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Sets New 12-Month High at $43.73Tourmaline Bio (NASDAQ:TRML) Sets New 52-Week High at $43.73March 1, 2024 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Short Interest UpdateTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 684,000 shares, a growth of 47.6% from the January 31st total of 463,500 shares. Approximately 4.4% of the shares of the company are short sold. Based on an average daily volume of 199,900 shares, the short-interest ratio is currently 3.4 days.March 1, 2024 | investing.comTourmaline Bio Inc (TRML)March 1, 2024 | finance.yahoo.comBullish Tourmaline Bio Insiders Loaded Up On US$643.3k Of StockFebruary 28, 2024 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Tourmaline Bio (TRML)February 28, 2024 | msn.comHere's What Could Help Tourmaline Bio, Inc. (TRML) Maintain Its Recent Price StrengthFebruary 28, 2024 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of "Buy" from AnalystsShares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have earned an average recommendation of "Buy" from the six brokerages that are covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts tFebruary 27, 2024 | globenewswire.comTourmaline Bio to Present at Upcoming Investor ConferencesFebruary 16, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Hits New 1-Year High at $40.76Tourmaline Bio (NASDAQ:TRML) Sets New 52-Week High at $40.76February 14, 2024 | finance.yahoo.comTRML Mar 2024 35.000 callFebruary 13, 2024 | finance.yahoo.comTRML Sep 2024 30.000 callFebruary 13, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Trading 2.4% Higher Tourmaline Bio (NASDAQ:TRML) Shares Up 2.4%February 13, 2024 | finance.yahoo.comTRML Feb 2024 30.000 callFebruary 13, 2024 | finance.yahoo.comTRML Mar 2024 40.000 putFebruary 8, 2024 | msn.comWhat Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing'February 8, 2024 | marketbeat.comLeerink Partnrs Comments on Tourmaline Bio, Inc.'s FY2024 Earnings (NASDAQ:TRML)Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for Tourmaline Bio in a research report issued to clients and investors on Monday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company wiFebruary 7, 2024 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Forecasted to Post Q1 2024 Earnings of ($0.62) Per ShareTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2024 earnings estimates for Tourmaline Bio in a note issued to investors on Monday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share o Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address Wall Street legend who predicted 2021 tech crash issues new warning (Ad)People around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history. Watch his stock warning right here, 100% free of charge TRML Media Mentions By Week TRML Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRML News Sentiment▼1.150.55▲Average Medical News Sentiment TRML News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRML Articles This Week▼143▲TRML Articles Average Week Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TScan Therapeutics News iTeos Therapeutics News Lexeo Therapeutics News Aura Biosciences News Replimune Group News Solid Biosciences News Jasper Therapeutics News Adaptive Biotechnologies News Tenaya Therapeutics News Black Diamond Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRML) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsTop 5 AI Stocks to Buy for 2024Market Moving TrendsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 Tech Stocks to Buy for 2024Daily Market AlertsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
